Oruka Therapeutics (ORKA) Income from Continuing Operations (2010 - 2024)
Oruka Therapeutics' (ORKA) quarterly Income from Continuing Operations came in at 18078000.0 in Q2 2024, down 1085.44% year-on-year from 1834505.59 in Q3 2023, and down 157.93% quarter-over-quarter from 7009000.0 in Q1 2024.
Oruka Therapeutics (ORKA) Income from Continuing Operations (2010 - 2024) Analysis & Trends
Oruka Therapeutics' Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 18078000.0 for Q2 2024.
- On a quarterly basis, Income from Continuing Operations fell 1085.44% year-over-year to 18078000.0 in Q2 2024; TTM through Jun 2024 was 27966000.0, a 332.04% decrease from a year earlier, with the FY2023 full-year figure at 60870000.0, up 5.32% from the prior year.
- Income from Continuing Operations declined to 18078000.0 in Q2 2024 per ORKA's latest filing, from 7009000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1115000.0 in Q4 2023 and bottomed at 18078000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 2848500.0 (2022), against an average of 3921166.67.
- Across the five-year window, Income from Continuing Operations soared 79.32% in 2022 and plunged 1085.44% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 5244000.0 in 2020, then decreased by 8.24% to 5676000.0 in 2021, then surged by 79.32% to 1174000.0 in 2022, then rose by 5.03% to 1115000.0 in 2023, then sank by 1521.35% to 18078000.0 in 2024.
- Per Business Quant, the three latest ORKA Income from Continuing Operations figures stand at 18078000.0 (Q2 2024), 7009000.0 (Q1 2024), and 1115000.0 (Q4 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Oruka Therapeutics | 36.09 Mn | -795.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -18.08 Mn |
| Mar 31, 2024 | -7.01 Mn |
| Dec 31, 2023 | -1.12 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | -1.53 Mn |
| Mar 31, 2023 | -1.38 Mn |
| Dec 31, 2022 | -1.17 Mn |
| Sep 30, 2022 | -2.40 Mn |
| Jun 30, 2022 | -3.65 Mn |
| Mar 31, 2022 | -3.30 Mn |
| Dec 31, 2021 | -5.68 Mn |
| Sep 30, 2021 | -4.71 Mn |
| Jun 30, 2021 | -4.83 Mn |
| Mar 31, 2021 | -4.11 Mn |
| Dec 31, 2020 | -5.24 Mn |
| Sep 30, 2020 | -1.99 Mn |
| Jun 30, 2020 | -1.30 Mn |
| Mar 31, 2020 | -1.32 Mn |
| Dec 31, 2019 | -1.23 Mn |
| Sep 30, 2019 | -1.16 Mn |